Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Sekisui XenoTech Adds Rodent, Monkey Hepatocytes to Patented CryostaX® Product Line
Credit: Sekisui XenoTech
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Sekisui XenoTech’s CryostaX® in vitro drug discovery and preclinical drug development test systems now includes pooled Sprague-Dawley rat and CD-1 mouse hepatocytes. Cynomolgus monkey hepatocytes will also be added soon.
CryostaX® hepatocytes are prepared using a patented process that produces unique cryopreserved cell pellets. This single-freeze process:
• provides greater convenience, since there is no need to thaw the hepatocytes to get them out of the vial, which can potentially lead to ‘over-thawing’ and cell damage,
• versatile pooling options in lot sizes that can last for years,
• and minimizes cryopreservation freeze-thaw injury to the cells for high viability, cell yield and enzymatic activity for longer-term, consistent test results.
Data indicates benefits to CYP, SULT and UGT activity and extended culture up to 48 hours without a medium change. Eliminating the need for water baths in or near culture hoods and incubators also eliminates a significant source of contamination. Due to the clear superiority of CryostaX® products, the company foresees the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods.
CryostaX® hepatocytes are prepared using a patented process that produces unique cryopreserved cell pellets. This single-freeze process:
• provides greater convenience, since there is no need to thaw the hepatocytes to get them out of the vial, which can potentially lead to ‘over-thawing’ and cell damage,
• versatile pooling options in lot sizes that can last for years,
• and minimizes cryopreservation freeze-thaw injury to the cells for high viability, cell yield and enzymatic activity for longer-term, consistent test results.
Data indicates benefits to CYP, SULT and UGT activity and extended culture up to 48 hours without a medium change. Eliminating the need for water baths in or near culture hoods and incubators also eliminates a significant source of contamination. Due to the clear superiority of CryostaX® products, the company foresees the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods.
